

# Real-world data

## GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System



**SURPASS\* is an observational, prospective, single-arm post-market registry. 20 European sites in seven countries are included.**

# ZERO

- Type Ia and Type III endoleaks
- Fractures
- Device compressions
- Ruptures

# 100%

Successful deployment

# 98.4%


With no device-related issues

# 97.2%

Freedom from serious access complications

### Aortic pathology treated:

- Treatment of Type B dissection (complicated / uncomplicated)
- Descending thoracic aortic aneurysms (Including ruptures)
- Penetrating aortic ulcers
- Traumatic aortic transection
- Intramural hematoma
- Pseudoaneurysm



# 98.4%

Reported that proximal wall apposition was acceptable at procedural completion

# 1.38

Devices per procedure

# 92.9%

No rapid pacing used

\* Rates are based on physician experience as reported for 127 subjects in Europe within a 30 day follow-up period. European-Post Approval Registry: Observational Registry Characterizing the Performance and Feature Use of the GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System. (data on file 2017; W.L. Gore & Associates, Inc; Flagstaff, AZ.)

**INDICATIONS FOR USE IN THE U.S.:** The GORE® TAG® Thoracic Stent Graft is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: adequate iliac / femoral access, aortic inner diameter in the range of 16–42 mm,  $\geq 20$  mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac / femoral access,  $\geq 20$  mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16–42 mm. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to *Instructions for Use* at [goremedical.com](http://goremedical.com) for a complete description of all warnings, precautions, and adverse events. **INDICATIONS FOR USE UNDER CE MARK:** The GORE® TAG® Thoracic Stent Graft is indicated for endovascular repair of the descending thoracic aorta. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at [goremedical.com](http://goremedical.com) for a complete description of all warnings, precautions, and adverse events. Rx Only

Products listed may not be available in all markets.

GORE, ACTIVE CONTROL, TAG and designs are trademarks of W. L. Gore & Associates.  
© 2019 W. L. Gore & Associates, Inc. AY0121-EN4 NOVEMBER 2019



**W. L. GORE & ASSOCIATES, INC.**  
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)  
00800.6334.4673 (Europe)  
800.437.8181 (United States)  
928.779.2771 (United States)

[goremedical.com](http://goremedical.com)